Amazon Cloud Partnership Drives Cerner’s Shift to Digital Platform Company
Cerner announced a partnership with Amazon Web Services (AWS) one year ago. Cerner plans to...
Top Story
Featured Stories
Amazon Cloud Partnership Drives Cerner’s Shift to Digital Platform Company
Cerner announced a partnership with Amazon Web Services (AWS) one year ago. Cerner plans to leverage Amazon's artificial… Read more
ICER Releases Draft Evidence Report on Therapies for Lupus Nephritis
Also this morning, we published our Draft Evidence Report assessing the comparative clinical effectiveness and value of… Read more
ICER Publishes Evidence Report on Therapies for High Cholesterol
This morning ICER issued the Evidence Report assessing the comparative clinical effectiveness and value of inclisiran… Read more
Latest Stories
Amazon Cloud Partnership Drives Cerner’s Shift to Digital Platform Company
Cerner announced a partnership with Amazon Web Services (AWS) one year ago. Cerner plans to leverage Amazon's artificial intelligence capabilities and customer experience expertise to drive future growth for its health IT business. The linkage with Amazon includes moving many of Cerner’s solutions […]
ICER Releases Draft Evidence Report on Therapies for Lupus Nephritis
Also this morning, we published our Draft Evidence Report assessing the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals) and belimumab (Benlysta®, GlaxoSmithKline) for the treatment of lupus nephritis. We’re now accepting public comments through February […]
ICER Publishes Evidence Report on Therapies for High Cholesterol
This morning ICER issued the Evidence Report assessing the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol®, Esperion Therapeutics), and bempedoic acid/ezetimibe (Nexlizet™, Esperion Therapeutics) for treating heterozygous familial hypercholesterolemia […]
Drug price hikes without new evidence upped spending by $1.2B
The Institute for Clinical and Economic Review (ICER) published its second-ever report on Unsupported Price Increases (UPI) last week, compiled from data supplied by SSR Health, which is part of the investment research firm SSR. While the medical pricing watchdog found that overall spending was […]
Value-Based Purchasing Rule For Medicaid Rx Drugs
Writing in Health Affairs, outgoing CMS Administrator Seema Verma touts how the Trump Administration helped paved the way for more outcomes-based contracts on prescription drugs by clarifying that these contracts won’t run afoul of the Medicaid “best price” provision -- provided that Medicaid […]
New Program in Pharmaceutical Value Assessment and Communications Launched by University of Florida
The University of Florida (UF) College of Pharmacy’s online graduate program in pharmaceutical outcomes and policy today announced the launch of a new track, Pharmaceutical Value Assessment and Communications. It is the only graduate program available that develops applied skills to translate data […]
How Will the Role of Medical Communication Professionals Evolve by 2025?
As a new year begins, this article dives deeper into 5 areas that global contributors identified when asked, “How will our field change in the next 5 years, and what are the top skills needed to be prepared to lead that change?” While the answers may not surprise you, what will is how consistent the […]
AMCP Executive Fellowship in Health Care Association Leadership
In January 2021, AMCP launched the Executive Fellowship in Health Care Association Leadership. This immersive, year-long training program provides a rich, in-depth learning experience for a pharmacist interested in a career in health care association leadership or managed care pharmacy. The program […]
Democrats Have Their Best Shot Yet at Letting Medicare Negotiate Drug Prices
Democrats have their best shot in more than a decade to deliver on one of the party’s central health care promises: allowing Medicare to directly negotiate prescription drug prices. But it’s far from guaranteed that they can deliver. Read more here. (Source: Nicholas Flokko; STAT; 1/21/21) […]
ISPOR Short Course: Intro To Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources
Real-world observational studies require strong principles of epidemiologic study design and complex analytical methods to strengthen causal inferences. This course will provide an overview of the structures of commonly encountered observational data sources with a focus on large administrative […]
